One-Time Cell Therapy Amtagvi Gets Accelerated Approval for

Amtagvi is a tumor-derived autologous T cell immunotherapy designed to deploy patient-specific T cells called TIL cells to locate and attack cancer cells.

Related Keywords

Alexandern Shoushtari , , Drug Administration , Boxed Warning , Melanoma Oncologist , Cellular Therapist , Memorial Sloan Kettering Cancer ,